The Rituximab in AAV trial was a randomized , double-blind , placebo-controlled trial comparing the rates of remission induction among patients treated with RTX ( n = 99 ) and patients treated with cyclophosphamide ( CYC ) followed by azathioprine ( AZA ) ( n = 98 ) .